XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Restatement of Condensed Consolidated Financial Statements (Unaudited) - Schedule of Restatement of Unaudited Consolidated Financial Statements (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 02, 2020
Feb. 13, 2020
Jan. 28, 2020
Feb. 04, 2019
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Cash and cash equivalents         $ 18,550,437       $ 18,550,437   $ 893,138  
Accounts receivable, net         5,349,876       5,349,876   131,382  
Inventory         10,110,786       10,110,786   197,168  
Prepaid expenses         2,890,549       2,890,549   362,566  
Total current assets         36,901,648       36,901,648   1,584,254  
Property and equipment, net         473,376       473,376   196,832  
Investment in joint venture         1,416,480       1,416,480   434,240  
Total assets         38,791,504       38,791,504   2,215,326  
Accounts payable         1,127,709       1,127,709   5,959  
Accrued expenses         691,385       691,385   200,788  
Accrued expenses (related party)         120,000       120,000   120,000  
Deferred revenue         1,045,548       1,045,548   1,323  
Total current liabilities         2,984,642       2,984,642   328,070  
Accrued expenses-long-term (related party)         80,000       80,000   150,000  
Total liabilities         3,064,642       3,064,642   478,070  
Commitments and contingencies (Note 1)                  
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 and 25,600 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively                 26  
Common Stock, $0.001 par value; 100,000,000 shares authorized; 27,991,042 and 17,342,922 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively         27,991       27,991   17,343  
Additional paid-in capital         46,726,869       46,726,869   26,687,701  
Accumulated deficit         (11,027,998)       (11,027,998)   (24,967,814)  
Total stockholders' equity         35,726,862 $ 19,166,943 $ 4,805,806 $ 5,563,832 35,726,862 $ 4,805,806 1,737,256 $ (1,058,811)
Total liabilities and stockholders' equity         38,791,504       38,791,504   $ 2,215,326  
Net revenue         24,040,274   61,574   25,588,802 64,974    
Cost of revenue         5,975,305   38,809   6,457,045 39,261    
Gross profit         18,064,969   22,765   19,131,757 25,713    
Sales and marketing         390,191   252,076   658,674 508,179    
Administrative and general         2,191,034   807,769   3,650,518 1,448,132    
Research and development         750,249   312,590   1,150,271 659,896    
Depreciation and amortization         25,218   16,094   45,966 29,762    
Total operating expenses         3,356,692   1,388,529   5,505,429 2,645,969    
Income from operations         14,708,277   (1,365,764)   13,626,328 (2,620,256)    
Interest income         38,173   19,640   45,748 20,048    
Interest expense             (106,427)    
Gain on disposition of assets             850    
Gain (loss) on equity method investment in joint venture         258,559   1,728   267,740 (7,000)    
Total other expense (expense)         296,732   21,368   313,488 (92,529)    
Income (loss) before income taxes         15,005,009   (1,344,396)   13,939,816 (2,712,785)    
Provision for income taxes                
Net income         $ 15,005,009 (1,065,193) $ (1,344,396) (1,368,389) $ 13,939,816 $ (2,712,785)    
Basic income (loss) per common share         $ 0.54   $ (0.08)   $ 0.50 $ (0.16)    
Diluted income (loss) per common share         $ 0.51   $ (0.08)   $ 0.48 $ (0.16)    
Weighted average common shares outstanding basic         27,582,229   17,017,964   27,605,137 17,017,964    
Weighted average common shares outstanding diluted         29,152,222   17,017,964   29,094,475 17,017,964    
Stock-based compensation expense                 $ 1,124,242 $ 294,677    
Accretion of notes payable discount                 91,428    
Gain on disposition of assets             (850)    
Loss (gain) from equity method investment                 (267,740) 7,000    
Accounts and other receivable                 (5,218,494) (42,065)    
Prepaid and other assets                 (2,527,983) (183,446)    
Inventory                 (10,030,838) 9,920    
Deffered revenue                 1,044,225    
Accounts payable and accrued expenses                 1,542,347 (191,332)    
Net cash used in operating activities                 (348,459) (2,697,691)    
Purchase of property and equipment                 (205,290) (52,775)    
Investment in joint venture                 (714,500) (247,000)    
Net cash used in investing activities                 (919,790) (299,775)    
Proceeds from sale of common stock $ 4,230,000 $ 10,240,002 $ 5,000,003 $ 5,496,002         19,470,005 5,496,002    
Proceeds from sale of preferred stock                 1,000,000    
Proceeds from exercise of options and warrants                 913,465    
Payment of offering costs                 (1,457,922) (592,764)    
Net cash provided by financing activities                 18,925,548 5,903,238    
Net increase in cash and cash equivalents                 17,657,299 2,905,772    
Cash and cash equivalents at beginning of period           893,138   $ 950,237 893,138 950,237    
Cash and cash equivalents at end of period         18,550,437   $ 3,856,009   18,550,437 $ 3,856,009    
As Previously Reported [Member]                        
Cash and cash equivalents         18,550,437       18,550,437      
Accounts receivable, net         5,349,876       5,349,876      
Inventory         10,110,786       10,110,786      
Prepaid expenses         521,180       521,180      
Total current assets         34,532,279       34,532,279      
Property and equipment, net         473,376       473,376      
Investment in joint venture         1,416,480       1,416,480      
Total assets         36,422,135       36,422,135      
Accounts payable         1,127,709       1,127,709      
Accrued expenses         691,385       691,385      
Accrued expenses (related party)         120,000       120,000      
Deferred revenue         1,045,548       1,045,548      
Total current liabilities         2,984,642       2,984,642      
Accrued expenses-long-term (related party)         80,000       80,000      
Total liabilities         3,064,642       3,064,642      
Commitments and contingencies (Note 1)                    
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 and 25,600 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively                    
Common Stock, $0.001 par value; 100,000,000 shares authorized; 27,991,042 and 17,342,922 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively         27,991       27,991      
Additional paid-in capital         46,726,869       46,726,869      
Accumulated deficit         (13,397,367)       (13,397,367)      
Total stockholders' equity         33,357,493       33,357,493      
Total liabilities and stockholders' equity         36,422,135       36,422,135      
Net revenue         24,040,274       25,588,802      
Cost of revenue         8,344,674       8,826,414      
Gross profit         15,695,600       16,762,388      
Sales and marketing         390,191       658,674      
Administrative and general         2,191,034       3,650,518      
Research and development         750,249       1,150,271      
Depreciation and amortization         25,218       45,966      
Total operating expenses         3,356,692       5,505,429      
Income from operations         12,338,908       11,256,959      
Interest income         38,173       45,748      
Interest expense                    
Gain on disposition of assets                    
Gain (loss) on equity method investment in joint venture         258,559       267,740      
Total other expense (expense)         296,732       313,488      
Income (loss) before income taxes         12,635,640       11,570,447      
Provision for income taxes                    
Net income         $ 12,635,640       $ 11,570,447      
Basic income (loss) per common share         $ 0.46       $ 0.42      
Diluted income (loss) per common share         $ 0.43       $ 0.40      
Weighted average common shares outstanding basic         27,582,229       27,605,137      
Weighted average common shares outstanding diluted         29,152,222       29,094,475      
Stock-based compensation expense                 $ 1,124,242      
Accretion of notes payable discount                      
Gain on disposition of assets                    
Loss (gain) from equity method investment                 (267,740)      
Accounts and other receivable                 (5,218,494)      
Prepaid and other assets                 (158,614)      
Inventory                 (10,030,838)      
Deffered revenue                 1,044,225      
Accounts payable and accrued expenses                 1,542,347      
Net cash used in operating activities                 (348,459)      
Purchase of property and equipment                 (205,290)      
Investment in joint venture                 (714,500)      
Net cash used in investing activities                 (919,790)      
Proceeds from sale of common stock                 19,470,005      
Proceeds from sale of preferred stock                      
Proceeds from exercise of options and warrants                 913,465      
Payment of offering costs                 (1,457,922)      
Net cash provided by financing activities                 18,925,548      
Net increase in cash and cash equivalents                 17,657,299      
Cash and cash equivalents at beginning of period           893,138     893,138      
Cash and cash equivalents at end of period         18,550,437       18,550,437      
Adjustments [Member]                        
Cash and cash equivalents                    
Accounts receivable, net                    
Inventory                    
Prepaid expenses         2,369,369       2,369,369      
Total current assets         2,369,369       2,369,369      
Property and equipment, net                    
Investment in joint venture                    
Total assets         2,369,369       2,369,369      
Accounts payable                    
Accrued expenses                    
Accrued expenses (related party)                    
Deferred revenue                    
Total current liabilities                    
Accrued expenses-long-term (related party)                    
Total liabilities                    
Commitments and contingencies (Note 1)                    
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 and 25,600 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively                    
Common Stock, $0.001 par value; 100,000,000 shares authorized; 27,991,042 and 17,342,922 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively                    
Additional paid-in capital                    
Accumulated deficit         2,369,369       2,369,369      
Total stockholders' equity         2,369,369       2,369,369      
Total liabilities and stockholders' equity         2,369,369       2,369,369      
Net revenue                    
Cost of revenue         (2,369,369)       (2,369,369)      
Gross profit         2,369,369       2,369,369      
Sales and marketing                    
Administrative and general                    
Research and development                    
Depreciation and amortization                    
Total operating expenses                    
Income from operations         2,369,369       2,369,369      
Interest income                    
Interest expense                    
Gain on disposition of assets                    
Gain (loss) on equity method investment in joint venture                    
Income (loss) before income taxes         2,369,369       2,369,369      
Provision for income taxes                    
Net income         $ 2,369,369       $ 2,369,369      
Basic income (loss) per common share         $ 0.08       $ 0.08      
Diluted income (loss) per common share         $ 0.08       $ 0.08      
Weighted average common shares outstanding basic         27,582,229       27,605,137      
Weighted average common shares outstanding diluted         29,152,222       29,094,475      
Stock-based compensation expense                      
Accretion of notes payable discount                      
Gain on disposition of assets                    
Loss (gain) from equity method investment                      
Accounts and other receivable                      
Prepaid and other assets                 (2,369,369)      
Inventory                      
Deffered revenue                      
Accounts payable and accrued expenses                      
Net cash used in operating activities                      
Purchase of property and equipment                      
Investment in joint venture                      
Net cash used in investing activities                      
Proceeds from sale of common stock                      
Proceeds from sale of preferred stock                      
Proceeds from exercise of options and warrants                      
Payment of offering costs                      
Net cash provided by financing activities                      
Net increase in cash and cash equivalents                      
Cash and cash equivalents at beginning of period                    
Cash and cash equivalents at end of period